M
Mark E. Cooper
Researcher at University of Queensland
Publications - 1514
Citations - 141899
Mark E. Cooper is an academic researcher from University of Queensland. The author has contributed to research in topics: Diabetes mellitus & Diabetic nephropathy. The author has an hindex of 158, co-authored 1463 publications receiving 124887 citations. Previous affiliations of Mark E. Cooper include University of Cambridge & University of Adelaide.
Papers
More filters
Journal ArticleDOI
Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial
Vlado Perkovic,Robert D. Toto,Mark E. Cooper,Johannes F.E. Mann,Julio Rosenstock,Darren K. McGuire,Steven E. Kahn,Nikolaus Marx,John H. Alexander,Bernard Zinman,Bernard Zinman,Egon Pfarr,Sven Schnaidt,Thomas Meinicke,Maximillian von Eynatten,Jyothis T. George,Odd Erik Johansen,Christoph Wanner +17 more
TL;DR: Across all GFR categories, in participants with type 2 diabetes and CKD and/or CV disease, there was no difference in risk for linagliptin versus placebo on CV and kidney events, and AEs were balanced among groups overall and across eGFR categories.
Journal ArticleDOI
Urotensin II receptor antagonism confers vasoprotective effects in diabetes associated atherosclerosis: studies in humans and in a mouse model of diabetes.
Anna M.D. Watson,Murat Olukman,Christine Koulis,Yugang Tu,D Samijono,Derek Y.C. Yuen,Corina Lee,David J. Behm,Mark E. Cooper,Karin Jandeleit-Dahm,Anna C. Calkin,Terri J. Allen +11 more
TL;DR: This is the first report to demonstrate that UII is increased in diabetes-associated atherosclerosis in humans and rodents and UII receptor antagonism in diabetic Apoe KO mice significantly attenuated diabetes- associated Atherosclerosis and aortic staining.
Journal ArticleDOI
Using label-free screening technology to improve efficiency in drug discovery
Reena Halai,Mark E. Cooper +1 more
TL;DR: This review highlights the label-free approaches in the context of various applications and indicates that these new technology platforms are more likely to complement, rather than replace, traditional screening platforms.
Journal ArticleDOI
Cardiac Stress and Inflammatory Markers as Predictors of Heart Failure in Patients With Type 2 Diabetes: The ADVANCE Trial.
Toshiaki Ohkuma,Min Jun,Mark Woodward,Mark Woodward,Mark Woodward,Sophia Zoungas,Sophia Zoungas,Mark E. Cooper,Diederick E. Grobbee,Pavel Hamet,Giuseppe Mancia,Bryan Williams,Paul Welsh,Naveed Sattar,Jonathan E. Shaw,Kazem Rahimi,John Chalmers +16 more
TL;DR: Only NT-proBNP strongly and consistently improved the prediction of heart failure in patients with type 2 diabetes beyond a wide range of clinical risk factors and biomarkers.
Journal ArticleDOI
Poor prognosis in proteinuric type 2 diabetic patients with retinopathy: insights from the RENAAL study
TL;DR: The presence of diabetic retinopathy at baseline is associated with more proteinuria, lower GFR, and a higher risk for ESRD and death in type 2 diabetic patients.